Nov 24, 2021 7:00 am EST Castle Biosciences Presents Data Reinforcing the Clinical Utility of Its DecisionDx® Dermatologic Portfolio
Nov 19, 2021 7:00 am EST Data Demonstrating DecisionDx®-Melanoma Was a Significant, Independent Predictor of Metastatic Recurrence in Stage I-III Cutaneous Melanoma Published in Future Oncology
Nov 10, 2021 7:00 am EST Castle Biosciences to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
Nov 8, 2021 7:00 am EST Castle Biosciences Releases Inaugural Environmental, Social and Governance (ESG) Report
Nov 5, 2021 5:00 pm EDT Castle Biosciences Publishes DecisionDx®-Melanoma Study on the Validation of the i31-GEP SLNB Artificial Intelligence Algorithm
Nov 4, 2021 5:00 pm EDT Castle Biosciences’ Full DecisionDx® Portfolio of Dermatologic Tests to Be Interfaced with EMA® Electronic Health Records System
Oct 28, 2021 7:00 am EDT DecisionDx®-Melanoma Integrated Test Result Now Includes i31-GEP for Risk of Recurrence
